Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clinuvel Pharmaceuticals ( (AU:CUV) ) has provided an update.
Clinuvel Pharmaceuticals Limited, an Australian listed biopharmaceutical company trading on the ASX under the code CUV, focuses on developing and commercialising pharmaceutical products. The company has announced the lapse of 5,425 performance rights (security code CUVAK) as of 31 December 2025, due to the relevant conditions not being met or becoming incapable of being satisfied, resulting in a small reduction in its pool of potential equity-based remuneration instruments and no change to existing ordinary shares on issue.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$14.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is an Australian listed biopharmaceutical company (ASX: CUV).
Average Trading Volume: 96,669
Technical Sentiment Signal: Hold
Current Market Cap: A$628.5M
Learn more about CUV stock on TipRanks’ Stock Analysis page.